SARS-CoV-2 (2019-nCoV) Spike RBD-His Recombinant Protein

COVID-19 Spike RBD Research.
1/2
Price:
Size:
Number:

SARS-CoV-2 (2019-nCoV) Spike RBD-His Recombinant Protein: Product Information

Purity
> 95 % as determined by SDS-PAGE
Endotoxin
< 1.0 EU per μg of the protein as determined by the LAL method
Activity
Measured by its binding ability in a functional ELISA. Immobilized human ACE2 protein (Fc tag) (Cat: 10108-H05H) at 2 μg/mL (100 μL/well) can bind SARS-CoV-2/2019-nCoV Spike Protein (RBD, His Tag) (Cat: 40592-V08B), the EC50 of SARS-CoV-2/2019-nCoV Spike Protein (RBD, His Tag) (Cat: 40592-V08B) is 30-60 ng/mL.
Protein Construction
A DNA sequence encoding the SARS-CoV-2 (2019-nCoV) Spike Protein (RBD) (YP_009724390.1) (Arg319-Phe541) was expressed with a polyhistidine tag at the C-terminus.
Expressed Host
Baculovirus-Insect Cells
Species
2019-nCoV
Predicted N Terminal
Arg319
Molecule Mass
The recombinant SARS-CoV-2 (2019-nCoV) Spike Protein (RBD, His Tag) consists of 234 amino acids and predicts a molecular mass of 26.54 kDa.
Formulation
Lyophilized from sterile 20mM PB,300mM NaCl, pH 7.0,10% glycerol
Please contact us for any concerns or special requirements.
Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
Please refer to the specific buffer information in the hard copy of CoA.
Shipping
In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.
Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.
Stability & Storage
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃
Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Reconstitution
A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.

SARS-CoV-2 (2019-nCoV) Spike RBD-His Recombinant Protein: Images

Measured by its binding ability in a functional ELISA. Immobilized human ACE2 protein (Fc tag)(10108-H05H) at 2μg/mL (100μL/well) can bind 2019-nCoV Spike Protein (RBD, His Tag) (40592-V08B), the EC50 of 2019-nCoV Spike Protein (RBD, His Tag) (40592-V08B) is 35-70 ng/mL.

SARS-CoV-2 (2019-nCoV) Spike RBD-His Recombinant Protein: Synonyms

coronavirus spike Protein, 2019-nCoV; cov spike Protein, 2019-nCoV; ncov RBD Protein, 2019-nCoV; ncov s1 Protein, 2019-nCoV; ncov s2 Protein, 2019-nCoV; ncov spike Protein, 2019-nCoV; NCP-CoV RBD Protein, 2019-nCoV; NCP-CoV s1 Protein, 2019-nCoV; NCP-CoV s2 Protein, 2019-nCoV; NCP-CoV Spike Protein, 2019-nCoV; novel coronavirus RBD Protein, 2019-nCoV; novel coronavirus s1 Protein, 2019-nCoV; novel coronavirus s2 Protein, 2019-nCoV; novel coronavirus spike Protein, 2019-nCoV; RBD Protein, 2019-nCoV; S1 Protein, 2019-nCoV; S2 Protein, 2019-nCoV; Spike RBD Protein, 2019-nCoV

Coronavirus spike Background Information

The spike (S) glycoprotein of coronaviruses contains protrusions that will only bind to certain receptors on the host cell. Known receptors bind S1 are ACE2, angiotensin-converting enzyme 2; DPP4, dipeptidyl peptidase-4; APN, aminopeptidase N; CEACAM, carcinoembryonic antigen-related cell adhesion molecule 1; Sia, sialic acid; O-ac Sia, O-acetylated sialic acid. The spike is essential for both host specificity and viral infectivity. The term 'peplomer' is typically used to refer to a grouping of heterologous proteins on the virus surface that function together. The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. It's been reported that SARS-CoV-2 (COVID-19 coronavirus, 2019-nCoV) can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity. The main functions for the Spike protein are summarized as: Mediate receptor binding and membrane fusion; Defines the range of the hosts and specificity of the virus; Main component to bind with the neutralizing antibody; Key target for vaccine design; Can be transmitted between different hosts through gene recombination or mutation of the receptor binding domain (RBD), leading to a higher mortality rate.
References
  • Shen S, et al. (2007) Expression, glycosylation, and modification of the spike (S) glycoprotein of SARS CoV. Methods Mol Biol. 379: 127-35.
  • Du L, et al. (2009) The spike protein of SARS-CoV--a target for vaccine and therapeutic development. Nat Rev Microbiol. 7 (3): 226-36.
  • Xiao X, et al. (2004) The SARS-CoV S glycoprotein. Cell Mol Life Sci. 61 (19-20): 2428-30.

2019-nCoV Coronavirus spike Proteins

  • Discovery of Aptamers Targeting Receptor-Binding Domain of the SARS-CoV-2 Spike Glycoprotein
    Author
    Song, Y;Song, J;Wei, X;Huang, M;Sun, M;Zhu, L;Lin, B;Shen, H;Zhu, Z;Yang, C;
    Year
    2020
    Journal
    ChemRxiv
  • Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor
    Author
    Ye, L;Chen, X;Li, R;Pan, Z;Qian, C;Yang, Y;You, R;
    Year
    2020
    Journal
    medRxiv
  • Humanized Single Domain Antibodies Neutralize SARS-CoV-2 by Targeting Spike Receptor Binding Domain
    Author
    Chi, X;Liu, X;Wang, C;Zhang, X;Ren, L;Jin, Q;Wang, J;
    Year
    2020
    Journal
    bioRxiv
  • Identification of Human Single-Domain Antibodies against SARS-CoV-2
    Author
    Wu, Y;Li, C;Xia, S;Tian, X;Kong, Y;Wang, Z;Gu, C;Zhang, R;Tu, C;Xie, Y;Yang, Z;Lu, L;Jiang, S;Ying, T;
    Year
    2020
    Journal
    Cell Host Microbe
  • Isolation of a human monoclonal antibody specific for the receptor binding domain of SARS-CoV-2 using a competitive phage biopanning strategy
    Author
    Zeng, X;Li, L;Lin, J;Li, X;Liu, B;Kong, Y;Zeng, S;Du, J;Xiao, H;Zhang, T;Zhang, S;Liu, J;
    Year
    2020
    Journal
    Antibody Therapeutics
  • Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells
    Author
    Cao, Y;Su, B;Guo, X;Sun, W;Deng, Y;Bao, L;Zhu, Q;Zhang, X;Zheng, Y;Geng, C;Chai, X;He, R;Li, X;Lv, Q;Zhu, H;Deng, W;Xu, Y;Wang, Y;Qiao, L;Tan, Y;Song, L;Wang, G;Du, X;Gao, N;Liu, J;Xiao, J;Su, XD;Du, Z;Feng, Y;Qin, C;Qin, C;Jin, R;Xie, XS;
    Year
    2020
    Journal
    Cell
  • Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 infection
    Author
    Simon, D;Tascilar, K;Krönk, G;Kleyer, A;Zaiss, M;Heppt, F;Meder, C;Atreya, R;Klenske, E;Dietrich, P;Abdullah, A;Kliem, T;Corte, G;Morf, H;Leppkes, M;Kremer, A;Ramming, A;Pachowsky, M;Schuch, F;Ronneberger, M;Kleinert, S;Maier, C;Hueber, A;Manger, K;Manger, B;Berking, C;Tenbusch, M;Überla, K;Sticherling, M;Neurath, M;Schett, G;
    Year
    2020
    Journal
    Research Square
  • SARS-CoV-2-specific antibody detection for sero-epidemiology: a multiplex analysis approach accounting for accurate seroprevalence
    Author
    den Hartog, G;Schepp, R;Kuijer, M;GeurtsvanKessel, C;van Beek, J;Rots, N;Koopmans, M;van der Klis, F;van Binnendijk, R;
    Year
    2020
    Journal
    medRxiv
  • Array-based analysis of SARS-CoV-2, other coronaviruses, and influenza antibodies in convalescent COVID-19 patients
    Author
    Steiner, D;Cognetti, J;Luta, E;Klose, A;Bucukovski, J;Bryan, M;Schmuke, J;Nguyen-Contant, P;Sangster, M;Topham, D;Miller, B;
    Year
    2020
    Journal
    bioRxiv
  • Insight into vaccine development for Alpha-coronaviruses based on structural and immunological analyses of spike proteins
    Author
    Shi, Y;Shi, J;Sun, L;Tan, Y;Wang, G;Guo, F;Hu, G;Fu, Y;Fu, Z;Xiao, S;Peng, G;
    Year
    2020
    Journal
    bioRxiv
  • Investigation of ACE2 N-terminal fragments binding to SARS-CoV-2 Spike RBD
    Author
    Zhang, G;Pomplun, S;Loftis, A;Tan, X;Loas, A;Pentelute, B;
    Year
    2020
    Journal
    bioRxiv
    Application
    BLI
  • Structures of potent and convergent neutralizing antibodies bound to the SARS-CoV-2 spike unveil a unique epitope responsible for exceptional potency
    Author
    Du, S;Cao, Y;Zhu, Q;Wang, G;Du, X;He, R;Xu, H;Zheng, Y;Wang, B;Bai, Y;Ji, C;Yisimayi, A;Wang, Q;Gao, N;Xie, X;Su, X;Xiao, J;
    Year
    2020
    Journal
    bioRxiv
    Application
    Elisa; SPR
  • Structures of potent and convergent neutralizing antibodies bound to the SARS-CoV-2 spike unveil a unique epitope responsible for exceptional potency
    Author
    Du, S;Cao, Y;Zhu, Q;Wang, G;Du, X;He, R;Xu, H;Zheng, Y;Wang, B;Bai, Y;Ji, C;Yisimayi, A;Wang, Q;Gao, N;Xie, X;Su, X;Xiao, J;
    Year
    2020
    Journal
    bioRxiv
Add to Cart Successfully Add to Cart Failed Shopping cart is being updated, please wait U.S.A.